Co. Advancing Drug Class With Broad Potential
September 14, 2022 (Investorideas.com Newswire) This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report.
BTIG initiated coverage on Annexon Inc. (ANNX:NASDAQ) with a Buy rating and a $15 per share price target, reported analyst Dr. Thomas Shrader in a September 9, 2022 research note.
In comparison, the current share price of the biotech, developing new complement medicines for patients with classical complement-mediated disorders of the body, brain and eyes, is around $5.85.
The method of action of Annexon’s therapeutics, inhibiting complement component 1q (C1q) of the classical complement cascade, “has broad potential,” Shrader highlighted. The biotech is currently trialing five C1q-targeting drugs in eight indications and continues identifying indications and patient groups in which C1q intervention will have a meaningful impact.
Results from many of these studies are expected between now and year-end 2023, each readout acting as a potential stock-moving catalyst.
“Strongly validating clinical data indicating C1q modulation alters disease progression in essentially any of these programs should reflect on related programs and result in a significant value inflection,” Shrader wrote.
The analyst explained that the C1q complement factor, which sets the complement cascade into motion, is overexpressed in multiple disease states. The complement cascade enhances the ability of antibodies and phagocytic cells to, in part, clear microbes and damaged cells from an organism. It also promotes inflammation.
Because ANX005 in Guillain-Barre syndrome is Annexon’s lead overall program and lead autoimmune program, a positive readout “has the potential to support registration and opens the door to several other antibody-mediated autoimmune conditions,” Shrader purported. Were efficacy to be shown in Guillain-Barre, it would derisk many other indications.
The early data are positive, showing the drug candidates greatly reduced C1q activity and inflammation and “support high target engagement,” Shrader relayed. “Similarly, the greater clinical effects seen for patients with high complement activity (above average) relative to low activity seem a good start to proof of mechanism.” Also, drug administration has been shown to be safe.
As for what is coming up for Annexon, catalysts include:
H2/22: Initial Phase 2 data for intravenous ANX005 in warm autoimmune hemolytic anemia
H2/22: Initial Phase 1b data for subcutaneous ANX009 in lupus nephritis
2023: Initial Phase 2/3 data for intravenous ANX005 in Guillain-Barre syndrome
2023: Initial Phase 2a data for intravenous ANX005 for amyotrophic lateral sclerosis
2023: Initial Phase 2 data for intravitreally injected ANX007 in geographic atrophy secondary to age-related macular degeneration
“The good news is that the data answering many of the key questions covering the role of C1q in various disease states is expected in the next 18 months,” Shrader wrote.
1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with: None. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures For BTIG Research, Annexon Inc., September 9, 2022
Analyst Certification: I, Thomas Shrader, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
I, Sung Jun Hong, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
Company-Specific Regulatory Disclosures: BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from:
Annexon, Inc. (ANNX) BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Alector Inc. (ALEC)
BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Biogen, Inc. (BIIB)
BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Denali Therapeutics Inc. (DNLI)
BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Silence Therapeutics (SLN)
BTIG LLC had an investment banking services client relationship during the past 12 months with: Silence Therapeutics (SLN)
BTIG LLC has received compensation for investment banking services in the past 12 months from: Silence Therapeutics (SLN)
General Disclosures: Research reports produced by BTIG LLC (“BTIG”) are published for and intended to be distributed solely to BTIG institutional and corporate clients. Recipients of BTIG reports will not be considered clients of BTIG solely because they may have received such BTIG report.
To the extent recipient accesses BTIG research, whether on a BTIG research website or through a third-party platform, BTIG is able to search, filter, download and review information on the readership of BTIG’s research, including the specific research consumed and the name, company name, email address and, in certain circumstances, the location of the individual who accessed the research (the “Readership Information”). Recipient consents to BTIG’s receipt of the Readership Information, including receipt of that information from a third party.
The research analyst(s) responsible for the preparation of this report receives compensation based upon a variety of factors, including the quality and accuracy of research, internal/client feedback, and overall Firm revenues. BTIG reports are based on public information and BTIG considers the same to be reliable, comprehensive information, but makes no representation or warranty that the reports are accurate or complete. BTIG opinions and information provided in this report are as of the date of the report and may change without notice. An issuer may be classified as “Under Review” or “Research Restricted”. In these cases, investors should consider any previous investment recommendation and/or rating to a subject company/issuer to no longer be current and should not be relied upon nor considered a solicitation.
This research report is not an offer to buy or sell or solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal. This research report was not drafted specifically for any particular individual or entity and is not a personal recommendation to participate in any particular trading strategy or transaction. Any recipient of this research report should obtain independent advice specific to their personal circumstances before undertaking any investment activity and must make their own independent evaluation of any securities or financial instruments.
Facts, views or opinions presented in this report have not been reviewed by, and may not reflect information known to, employees or other professionals in the “BTIG Group” (BTIG Group includes, but is not limited to, BTIG and its parents, subsidiaries and/ or affiliates). BTIG Group employees, including Sales Representatives and Traders, may provide oral or written commentary or advice that may be inconsistent with the opinions and/or views expressed in this research report. BTIG Group employees and/or its affiliates not involved in the preparation of this research report may have investments in securities or derivatives of securities of companies mentioned in this report that are inconsistent with the views discussed in this report.
Investors in securities products bear certain risks in conjunction with those investments. The value of, and income from, any investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors within or beyond the companies’ control. Recipient of the research reports should be aware that investments in securities may pose significant risks due to the inherent uncertainty associated with relying on forecasts of various factors that can affect the earnings, cash flow and overall valuation of a company.
Any investment in securities should be undertaken only upon consideration of issues relating to the recipient’s overall investment portfolio and objectives (such as diversification by asset class, industry or company) as well as time horizon and liquidity needs. Further, past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. There may be time limitations on the exercise of options or other rights in any securities transactions. Investing in foreign markets and securities, including ADRs, is subject to additional risks such as currency fluctuation, limited information, political instability, economic risk, and the potential for illiquid markets. Investing in emerging markets may accentuate these risks. Non-U.S. reporting issuers of foreign securities, however, may not make regular or complete public disclosure relating to their financial condition or the securities that they issue.
The trademarks and service marks contained herein are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability of any damages of any kind relating to such data. The report or any portion hereof may not be reprinted, sold or redistributed without the written consent of BTIG. This report is intended only for use by the recipient. The recipient acknowledges that all research and analysis in this report are the property of BTIG and agrees to limit the use of all publications received from BTIG within his, or her or its, own company or organization. No rights are given for passing on, transmitting, re transmitting or reselling the information provided.
This news is published on the Investorideas.com Newswire – a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
BiotechIndustryStocks.com – investing ideas in biotechnology stocks, medical technology and life sciences
Like Biotech Stocks? View our Biotech Stocks Directory